Report for the Fourth Quarter and Full Year 2012

Stockholm, 21 February 2013
Geoffrey  McDonough, CEO: "2012 was a year  of significant progress for Sobi. We
recorded  double  digit  growth  for  Kineret®  and  Orfadin®,  revitalized  our
distribution  partnerships  and  extended  our  ReFacto® manufacturing agreement
through  2020. We  made  significant  progress  with  our  pipeline and released
positive  top-line  data  for  both  of  our  long-lasting  clotting factors for
haemophilia in development with Biogen Idec, and with the approval of Kineret in
NOMID(1))  by the US FDA. Finally, we  have achieved our cost discipline targets
for  the year, and have executed on our strategy to improve the gross margin. At
the outset of 2013 we initiated an important partnership in the Partner Products
portfolio  with Valeant®/PharmaSwiss,  and we  have also  signed a collaboration
with Savient for the co-promotion of Kineret in the United States. Today we will
offer  an additional placement of  up to SEK 200 M  against our existing bond to
ensure that we can meet the opportunities presented by the pace and scale of our
Haemophilia programs."

Fourth quarter
  * Total revenues increased by 8% to SEK 471.9 M (436.4).  The corresponding
    period in 2011 included revenues from co-promotion for ReFacto AF/BeneFIX®
    and discontinued products of SEK 26 M.
  * Product revenues(2)) increased by 8% to SEK 356 M (330.1), with double digit
    growth for Kineret and Orfadin.
  * Gross margin increased to 57% (41%) driven by efficiency gains in
    production, and completion of tech transfer for Kineret.
  * FDA approved Kineret for treatment of NOMID.
  * Write-down of intangible asset related to Multiferon® in the amount of SEK
    162 M.



Full year 2012
  * Total revenues increased to SEK 1,923.2 M (1,910.8). 2011 included revenues
    from co-promotion for ReFacto AF/BeneFIX and discontinued products of SEK
    150 M.
  * Operating expenses decreased by 5% to SEK 941.2 M (994.6), reflecting the
    ongoing streamlining of operations.
  * Gross margin at 54% (51%).
  * Sobi issued a 5-year senior unsecured bond loan in the amount of SEK 600 M.
  * Sobi and Biogen Idec announced positive top-line results from A-LONG and B-
    LONG phase III clinical studies of the companies' long-lasting recombinant
    coagulation factors, rFVIIIFc and rFIXFc. Both were effective in the control
    and prevention of bleeding, in routine prophylaxis and perioperative
    management, and were generally well-tolerated.


Outlook for 2013
  * Total revenues for the full year 2013 are expected to be in the range of SEK
    2,000 to 2,200 M
  * Revenues for

      * Core Products are expected to show high single-digit growth
      * Partner Products portfolio is expected to grow by about one third, and
      * ReFacto manufacturing and royalty are expected to show low single-digit
        growth.

  * Gross margin is expected to be in the range of 57-59%.


(1))   Neonatal Onset Multi-systemic Inflammatory Disorder (NOMID) is the most
severe form of CAPS (Cryopyrin Associated Periodic Syndromes)
(2))    Product revenues  include Core Products and Partner Products



Telephone conference at 2.00 p.m. CET

Financial  analysts and media are invited to a telephone conference at 2.00 p.m.
CET the same day, hosted by CEO Geoffrey McDonough, CFO Annika Muskantor and COO
Alan Raffensperger. The presentation will be held in English and can be followed
live  or afterwards on our website www.sobi.com. Slides used in the presentation
will be available on our website prior to the telephone conference.

Details for participation
Please call:
SE: +46850556476
UK: +442033645371
US: +18776792993

Yours sincerely,
Jorgen Winroth,
VP Investor Relations
Phone: +46 8 697 20 00



The  above  information  has  been  made  public  in accordance with the Swedish
Securities  Market  Act  and/or  the  Financial  Instruments  Trading  Act.  The
information  was released for  public distribution on  21 February 2013 at 8.30
CET.


Subscribe

Documents & Links